Eli Lilly and Co (NEOE:ZLLY) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEOE:ZLLY Eli Lilly and Co NEOE:ZLLY
75 GF Score
Price C$12.57
GF Value C$16.39
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (NEOE:ZLLY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.14 13.57 20.20 23.93 28.40

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.34 20.92 28.40 22.92 28.25

NEOE:ZLLY vs JNJ, ABBV, MRK: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


NEOE:ZLLY
75GF Score
Eli Lilly and Co NEOE:ZLLY
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=36.077/333.9520*333.9520
=36.077

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.415 241.428 8.873
201612 7.222 241.432 9.990
201703 6.626 243.801 9.076
201706 7.325 244.955 9.986
201709 6.579 246.819 8.902
201712 3.992 246.524 5.408
201803 6.115 249.554 8.183
201806 7.115 251.989 9.429
201809 6.740 252.439 8.916
201812 7.417 251.233 9.859
201903 6.919 254.202 9.090
201906 8.101 256.143 10.562
201909 7.895 256.759 10.269
201912 8.794 256.974 11.428
202003 8.973 258.115 11.609
202006 8.182 257.797 10.599
202009 8.333 260.280 10.692
202012 10.423 260.474 13.363
202103 9.375 264.877 11.820
202106 9.047 271.696 11.120
202109 9.422 274.310 11.471
202112 11.061 278.802 13.249
202203 10.908 287.504 12.670
202206 9.201 296.311 10.370
202209 10.245 296.808 11.527
202212 10.961 296.797 12.333
202303 10.543 301.836 11.665
202306 12.234 305.109 13.391
202309 14.284 307.789 15.498
202312 13.882 306.746 15.113
202403 13.132 312.332 14.041
202406 17.132 314.175 18.210
202409 17.122 315.301 18.135
202412 21.347 315.605 22.588
202503 20.291 319.799 21.189
202506 23.633 322.561 24.468
202509 27.091 324.800 27.854
202512 29.633 324.054 30.538
202603 30.321 330.213 30.664
202606 36.077 333.952 36.077

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Eli Lilly and Co (NEOE:ZLLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of C$12.57 is trading 23.3% below its estimated GF Value™ of C$16.39. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for NEOE:ZLLY:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: C$16.39 vs. price of C$12.57 (23.3% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the NEOE:ZLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
75GF Score

Get the complete analysis for NEOE:ZLLY

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$12.57
Price
C$16.39
GF Value